Follow-up of Immunological Pattern and Pregnancy Outcomes in Women Previously Received Placental Malaria Vaccine

Malaria in Pregnancy Clinical Trial

— PRIMVACLongT  

Official title:

Long Term Follow-up of Immunological Pattern and Pregnancy Outcomes in Women Previously Enrolled in a Phase 1b Clinical Trial With the PRIMVAC Placental Malaria Candidate Vaccine

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05426187
• Other study ID #: PRIMVAC Long Term study
• Status: Active, not recruiting
• Start date: February 18, 2022
• Est. completion date: December 31, 2024

Study information

• Verified date: April 2024
• Source: Groupe de Recherche Action en Sante
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Study Population: Participants of the previous PRIMVAC vaccine trial and women aged 18 to 35 years Sample Size: 90 Study duration: 21 months Subject duration: 12 months if pregnancy doesn't occurred. In case of pregnancy, the participant will be followed up until the delivery. Study Design: Long term observational study comparing the immunology trend of 3 groups of i) women who received the PRIMVAC Vaccine or Placebo during the phase 1b trial in Burkina Faso; ii) women of the same age and nulligravid who did not participate in the phase 1b trial iii) women of the same age and primigravid who did not participate in the phase 1b trial Co Primary objectives - To assess the dynamics of humoral immune response to the vaccine antigen during long term follow up of the study participants - To evaluate the functional durability of the humoral immune responses of women who participated in the phase 1b vaccine trial compared to women of the same age Secondary objectives - To assess the cellular immune response during the follow-up period - To assess the incidence of clinical malaria on study participants - To assess the prevalence of Placental Malaria in study participants and adverse outcomes such as maternal anemia, low birth weight, stillbirth and prematurity.

Description:

It is a long-term observational study comparing the immunology trend of 3 groups of women: - Women who received the PRIMVAC Vaccine or Placebo during the phase 1b trial in Burkina Faso - Women of the same age and nulligravid who did not participate in the phase 1b trial - Women of the same age and primigravid who did not participate in the phase 1b trial The proposed cohort study will build on the previous phase 1b study which was conducted within the health district of Saponé (ClinicalTrials.gov Identifier: NCT02658253). The enrolment and follow up of the subjects will last 12 months. Pregnancy which occurred during the follow up period will monitored until the delivery. An additional six months is necessary for sample analysis in the laboratory, the data analysis and the preparation of reports and publications.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 90
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2024
• Gender: Female
• Age group: 18 Years to 35 Years

Eligibility

Inclusion Criteria:

• Any participant of the previous PRIMVAC vaccine phase Ib trial
• Nulligravid and primigravid women aged 18-35 years
• Residing in study region and environs
• Available and willing to participate in follow-up for the duration of study
• Participant who accept blood sample collection
• Appear to be in generally good health based on clinical and laboratory investigation
• Signed informed consent

Exclusion Criteria:

• Participants who refused to sign informed consent
• Use of an investigational or non-registered drug or vaccine other than the previous study vaccine
• Chronic administration of immunosuppressants or other immune-modifying drugs
• Confirmed or suspected immunosuppressive or immunodeficient condition
• Confirmed or suspected autoimmune disease
• Simultaneous participation in any interventional clinical trial
• Women of control groups with positif pregnancy test at the enrolment

Related Conditions & MeSH terms

• Malaria
• Malaria in Pregnancy

Locations

Country	Name	City	State
Burkina Faso	Groupe de Recherche Action en Santé	Ouagadougou

Sponsors (3)

Lead Sponsor	Collaborator
Groupe de Recherche Action en Sante	European Vaccine Initiative, Institut National de la Santé Et de la Recherche Médicale, France

Country where clinical trial is conducted

Burkina Faso, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Geometric mean titer of antibodies	Level of total Immunoglobin (IgG) and the level of the isotypic subtypes (IgG1, IgG2, IgG3, IgG4)	month 0
Primary	Geometric mean titer of antibodies	Level of total Immunoglobin (IgG) and the level of the isotypic subtypes (IgG1, IgG2, IgG3, IgG4)	month 6
Primary	Geometric mean titer of antibodies	Level of total Immunoglobin (IgG) and the level of the isotypic subtypes (IgG1, IgG2, IgG3, IgG4)	month 12
Primary	Cross-reactivity against different VAR2CSA variants expressed on the surface of erythrocytes parasitized by various strains of Plasmodium falciparum by flow cytometry	VAR2CSA variants	month 0
Primary	Percentage of binding inhibitory activity using various VAR2CSA expressing strains by CSA-binding inhibition assay (BIA) at different timepoints during the twelve months of follow up.	binding inhibitory activity	month 0